Alseres Pharmaceuticals (Alseres Pharmaceuticals) EBIT : $-0.54 Mil (TTM As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals EBIT?

Alseres Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2014 was $-0.32 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2014 was $-0.54 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alseres Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2014 was -623.10%. Alseres Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2014 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alseres Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2014 was -1,796.67%.

Alseres Pharmaceuticals EBIT Historical Data

The historical data trend for Alseres Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals EBIT Chart

Alseres Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

EBIT

Get a 7-Day Free Trial

-8.33

-3.12

-1.04

-1.21

-0.49

Alseres Pharmaceuticals Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
EBIT	Get a 7-Day Free Trial															-0.41	-0.25	0.36	-0.33	-0.32

Competitive Comparison of Alseres Pharmaceuticals's EBIT

For the Biotechnology subindustry, Alseres Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alseres Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's EV-to-EBIT falls into.

Alseres Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54 Mil.

Alseres Pharmaceuticals (OTCPK:ALSE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alseres Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2014 is calculated as:

	ROC % (Q: Jun. 2014 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2014 )	+	Invested Capital (Q: Jun. 2014 ))	/ count )
=	-1.268 * ( 1 - 0% )	/	( (0.145	+	0.262)	/ 2 )
=	-1.268	/	0.2035
=	-623.10 %

where

	Invested Capital		(Q: Mar. 2014 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.364	-	1.604	-	( 0.269	-	max(0, 1.69	-	0.305	+	0.269	))
=	0.145

	Invested Capital		(Q: Jun. 2014 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.279	-	1.608	-	( 0.187	-	max(0, 1.811	-	0.22	+	0.187	))
=	0.262

Note: The Operating Income data used here is four times the quarterly (Jun. 2014) data.

2. Joel Greenblatt's definition of Return on Capital:

Alseres Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2014 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2014 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2014		Q: Jun. 2014
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.268	/	( ( (0 + max(-1.654, 0))	+	(0 + max(-1.659, 0)) )	/	2 )
=	-1.268	/	( ( 0	+	0 )	/	2 )
=	-1.268	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Mar. 2014 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.036)	-	(1.604	+	0.074	+	0.012)
=	-1.654

	Working Capital		(Q: Jun. 2014 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.033)	-	(1.608	+	0.074	+	0.0099999999999998)
=	-1.659

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2014) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alseres Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2014 )
	=	-0.539	/	0.030
	=	-1,796.67 %

Alseres Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466

Website

http://www.alseres.com

Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.

Executives

Mark Jerome Pykett	officer: President and COO	223A MAIN ST, BOXFORD MA 021921
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Peter G Savas	director, officer: Chief Executive Officer	110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston	director	C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr	officer: Exec VP of Fin & Admin & CFO	C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon	officer: Chief Financial Officer	1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck	director	P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines

From GuruFocus

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-14-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009